# Cagrilintide

Canonical source: https://retacompare.com/encyclopedia/cagrilintide

Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.

Reference facts

Also known asAM833CategoryGLP-1 & MetabolicMechanism of actionLong-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.TargetsAMY1R, AMY3R, Calcitonin receptorIndications under research or approvedObesity (in combination with Semaglutide as CagriSema)Regulatory status (reference entry)Investigational (Phase 3 REDEFINE)Half-life~7 daysSequenceKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYSequence notes37-residue long-acting amylin analog with C18 fatty diacid linker; lysine substitutions and disulfide between Cys2-Cys7.Molecular weight (Da)3800Originator / sponsorNovo NordiskFirst reported2018
    Primary References

Cagrilintide Phase 1b, Lancet 2021

REDEFINE-1 CagriSema obesity (NCT05996848)


    Explore research articles about Cagrilintide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Cagrilintide Phase 1b, Lancet 2021: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/fulltext
- REDEFINE-1 CagriSema obesity (NCT05996848): https://clinicaltrials.gov/study/NCT05996848